S100A12 mediates aortic wall remodeling and aortic aneurysm

Prior research has shown that RAGE signaling contributes to vascular inflammation, particularly in atherosclerosis. However, the specific role of S100A12 as a RAGE ligand remains unclear. Established knowledge includes the involvement of RAGE in advanced glycation end product signaling and chronic inflammation. No prior work had resolved how S100A12 might influence vascular remodeling independently. This gap motivated the investigation into S100A12's function in vascular smooth muscle. The absence of S100A12 in murine models created a challenge for direct study. Researchers needed a system to observe S100A12's effects in vivo. Transgenic models provided a solution to test its pathogenic potential. This paper's contribution is the first direct evidence linking S100A12 to aortic wall changes.

The aim of this study was to determine how S100A12 influences vascular remodeling. Researchers focused on aortic wall structure and inflammatory pathways. They used transgenic mice to express human S100A12 in smooth muscle cells. This approach allowed them to observe effects not possible in native murine models. The specific problem addressed was whether S100A12 alone could drive pathological changes. The motivation stemmed from gaps in understanding RAGE ligand function. Human aortic tissue was also examined to validate findings. This study aimed to bridge in vitro and clinical observations.

Researchers generated transgenic mice with human S100A12 expression in vascular smooth muscle. The smooth muscle 22alpha promoter controlled expression. Histological analysis assessed aortic wall structure and elastic fiber organization. Matrix metalloproteinase-2 levels were measured using protein assays. Oxidative stress markers were quantified in cultured smooth muscle cells. Interleukin-6 production was analyzed in primary cell cultures. Thoracic aortic tissue from patients with aneurysms was collected for immunohistochemistry. This multi-modal approach combined in vivo and ex vivo techniques.

Transgenic mice showed aortic media thickening and elastic fiber disarray. Collagen deposition increased in the aortic wall of these mice. Latent matrix metalloproteinase-2 protein levels rose significantly. Smooth muscle stress fibers decreased in transgenic animals. In cultured cells, S100A12 increased interleukin-6 production. Transforming growth factor beta pathways activated in these cells. Metabolic activity rose with enhanced oxidative stress markers. Human aneurysm tissue showed elevated S100A12 in smooth muscle cells.

The authors propose that S100A12 expression alone is sufficient to activate pathogenic pathways. Vascular remodeling occurs through modulation of oxidative stress and inflammation. These findings suggest a direct role for S100A12 in aortic wall changes. The study supports a mechanistic link between S100A12 and aneurysm formation. No prior work had demonstrated this specific contribution of S100A12. The results trace directly to the observed histological and biochemical changes. The authors suggest these findings may inform future studies on aneurysm prevention. Their conclusions remain limited to the evidence presented in the study.